PMID- 28797967
OWN - NLM
STAT- MEDLINE
DCOM- 20180110
LR  - 20181202
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Print)
IS  - 0378-5173 (Linking)
VI  - 531
IP  - 1
DP  - 2017 Oct 5
TI  - Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention 
      of HIV-1 and HSV-2 infections in vitro.
PG  - 118-133
LID - S0378-5173(17)30768-8 [pii]
LID - 10.1016/j.ijpharm.2017.08.061 [doi]
AB  - Sexually transmitted infections affect hundreds of millions of people worldwide. 
      Both human immunodeficiency virus (HIV-1 and -2) and herpes simplex virus-2 
      (HSV-2) remain incurable, urging the development of new prevention strategies. 
      While current prophylactic technologies are dependent on strict user adherence to 
      achieve efficacy, there is a dearth of delivery vehicles that provide discreet 
      and convenient administration, combined with prolonged-delivery of active agents. 
      To address these needs, we created electrospun fibers (EFs) comprised of 
      FDA-approved polymers, poly(lactic-co-glycolic acid) (PLGA) and 
      poly(DL-lactide-co-epsilon-caprolactone) (PLCL), to provide sustained-release and in 
      vitro protection against HIV-1 and HSV-2. PLGA and PLCL EFs, incorporating the 
      antiretroviral, tenofovir disoproxil fumarate (TDF), exhibited sustained-release 
      for up to 4 weeks, and provided complete in vitro protection against HSV-2 and 
      HIV-1 for 24h and 1 wk, respectively, based on the doses tested. In vitro cell 
      culture and EpiVaginal tissue tests confirmed the safety of fibers in vaginal and 
      cervical cells, highlighting the potential of PLGA and PLCL EFs as multipurpose 
      next-generation drug delivery vehicles.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Tyo, Kevin M
AU  - Tyo KM
AD  - Department of Pharmacology and Toxicology, School of Medicine, University of 
      Louisville, KY, United States; Center for Predictive Medicine, Louisville, KY, 
      United States.
FAU - Vuong, Hung R
AU  - Vuong HR
AD  - Department of Biochemistry, School of Medicine, University of Louisville, KY, 
      United States.
FAU - Malik, Danial A
AU  - Malik DA
AD  - Department of Pharmacology and Toxicology, School of Medicine, University of 
      Louisville, KY, United States.
FAU - Sims, Lee B
AU  - Sims LB
AD  - Department of Bioengineering, Speed School of Engineering, University of 
      Louisville, Louisville, KY, United States.
FAU - Alatassi, Houda
AU  - Alatassi H
AD  - Department of Pathology, University of Louisville, Louisville, KY, United States.
FAU - Duan, Jinghua
AU  - Duan J
AD  - Department of Bioengineering, Speed School of Engineering, University of 
      Louisville, Louisville, KY, United States; Center for Predictive Medicine, 
      Louisville, KY, United States.
FAU - Watson, Walter H
AU  - Watson WH
AD  - Department of Pharmacology and Toxicology, School of Medicine, University of 
      Louisville, KY, United States; Department of Medicine, Division of 
      Gastroenterology, Hepatology and Nutrition, School of Medicine, University of 
      Louisville, KY, United States.
FAU - Steinbach-Rankins, Jill M
AU  - Steinbach-Rankins JM
AD  - Department of Bioengineering, Speed School of Engineering, University of 
      Louisville, Louisville, KY, United States; Department of Pharmacology and 
      Toxicology, School of Medicine, University of Louisville, KY, United States; 
      Department of Microbiology and Immunology, School of Medicine, University of 
      Louisville, KY, United States; Center for Predictive Medicine, Louisville, KY, 
      United States. Electronic address: jill.steinbach@louisville.edu.
LA  - eng
GR  - R25 CA134283/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170807
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Polyesters)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 70524-20-8 (lactide-caprolactone copolymer)
RN  - 99YXE507IL (Tenofovir)
SB  - IM
MH  - Anti-HIV Agents/*pharmacology
MH  - Antiviral Agents/*pharmacology
MH  - Cell Line
MH  - Cervix Uteri/cytology
MH  - Drug Carriers/*chemistry
MH  - Female
MH  - HIV-1/*drug effects
MH  - Herpesvirus 2, Human/*drug effects
MH  - Humans
MH  - Lactic Acid/chemistry
MH  - Polyesters/chemistry
MH  - Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Tenofovir/*pharmacology
MH  - Vagina/cytology
PMC - PMC5812024
MID - NIHMS939800
OTO - NOTNLM
OT  - Antiretroviral (ARV)
OT  - Drug delivery fiber
OT  - Electrospun fiber
OT  - HIV
OT  - HSV-2
OT  - MPT
OT  - Microbicide
OT  - Multipurpose prevention
OT  - Sexually transmitted infections (STIs)
OT  - Sustained release fiber
OT  - Tenofovir (TFV)
OT  - Tenofovir disoproxil fumarate (TDF)
EDAT- 2017/08/12 06:00
MHDA- 2018/01/11 06:00
PMCR- 2018/10/05
CRDT- 2017/08/12 06:00
PHST- 2017/06/02 00:00 [received]
PHST- 2017/07/27 00:00 [revised]
PHST- 2017/08/02 00:00 [accepted]
PHST- 2017/08/12 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
PHST- 2017/08/12 06:00 [entrez]
PHST- 2018/10/05 00:00 [pmc-release]
AID - S0378-5173(17)30768-8 [pii]
AID - 10.1016/j.ijpharm.2017.08.061 [doi]
PST - ppublish
SO  - Int J Pharm. 2017 Oct 5;531(1):118-133. doi: 10.1016/j.ijpharm.2017.08.061. Epub 
      2017 Aug 7.